Literature DB >> 5085238

Drug-metabolizing capacity in states of drug dependence and withdrawal.

B Ballinger, M Browning, K O'Malley, I H Stevenson.   

Abstract

1. Drug-metabolizing capacity was assessed in 8 barbiturate-dependent and in 3 Mandrax-dependent patients using, as indices, plasma antipyrine half-life and in some cases urinary output of 6beta-hydroxycortisol. For comparison, antipyrine half-life was also measured in volunteers before and after a period of taking hypnotic doses of these agents.2. Both indices indicated a very high drug-metabolizing capacity in the dependent subjects on admission, the antipyrine half-life value in the barbiturate patients being the shortest reported to date for any drug-exposed group. The urinary output of 6beta-hydroxycortisol was approximately three times that in a control population.3. This induction of drug-metabolizing capacity presumably contributed to the marked drug tolerance observed in the dependent patients.4. It appeared that drug-metabolizing capacity eventually returned to normal levels after withdrawal of the barbiturate.5. It is concluded that the abnormal drug-metabolizing capacity of dependent patients must be taken into account in assessing dose requirements for other drugs.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5085238      PMCID: PMC1665960          DOI: 10.1111/j.1476-5381.1972.tb08122.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  SIMILARITIES BETWEEN OXIDATIVE DRUG-METABOLIZING ENZYMES AND STEROID HYDROXYLASES IN LIVER MICROSOMES.

Authors:  R KUNTZMAN; M JACOBSON; K SCHNEIDMAN; A H CONNEY
Journal:  J Pharmacol Exp Ther       Date:  1964-12       Impact factor: 4.030

2.  A method for the analysis of urinary 17-hydroxycorticosteroids.

Authors:  J D FEW
Journal:  J Endocrinol       Date:  1961-03       Impact factor: 4.286

3.  Pharmacological implications of microsomal enzyme induction.

Authors:  A H Conney
Journal:  Pharmacol Rev       Date:  1967-09       Impact factor: 25.468

4.  Pharmacokinetic drug interactions.

Authors:  L F Prescott
Journal:  Lancet       Date:  1969-12-06       Impact factor: 79.321

5.  The drug history of psychiatric admissions.

Authors:  B R Ballinger; M J Stewart
Journal:  Br J Psychiatry       Date:  1971-12       Impact factor: 9.319

6.  The measurement, excretion, and source of urinary 6-hydroxycortisol in humans.

Authors:  K Thrasher; E E Werk; Y Choi; L J Sholiton; W Meyer; C Olinger
Journal:  Steroids       Date:  1969-11       Impact factor: 2.668

7.  Drug-metabolizing capacity and drug dependence.

Authors:  I H Stevenson; K O'Malley; B Ballinger
Journal:  Clin Sci       Date:  1970-09       Impact factor: 6.124

8.  Hepatic drug-metabolising enzyme activity and duration of hexobarbitone anaesthesia in barbitone-dependent and withdrawn rats.

Authors:  I H Stevenson; M J Turnbull
Journal:  Biochem Pharmacol       Date:  1968-11       Impact factor: 5.858

9.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.

Authors:  E S Vesell; J G Page
Journal:  J Clin Invest       Date:  1969-12       Impact factor: 14.808

10.  Effect of age and sex on human drug metabolism.

Authors:  K O'Malley; J Crooks; E Duke; I H Stevenson
Journal:  Br Med J       Date:  1971-09-11
  10 in total
  16 in total

1.  Serum concentrations of methaqualone after repeated oral doses of a combination formulation to human subjects.

Authors:  C White; E Doyle; L F Chasseaud; T Taylor
Journal:  Eur J Clin Pharmacol       Date:  1976-09-30       Impact factor: 2.953

2.  The clinical consequences of chronic hepatic enzyme induction by anticonvulsant drugs.

Authors:  A Richens
Journal:  Br J Clin Pharmacol       Date:  1974-06       Impact factor: 4.335

3.  Effect of long-term phenothiazine treatment on drug metabolism.

Authors:  T Kolakowska; M Franklin; B Alapin
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

Review 4.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

5.  Methaqualone pharmacokinetics after single- and multiple-dose administration in man.

Authors:  R K Nayak; R D Smyth; J H Chamberlain; A Polk; A F DeLong; T Herczeg; P B Chemburkar; R S Joslin; N H Reavey-Cantwell
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

6.  Antipyrine clearance during occupational exposure to styrene.

Authors:  M Døssing
Journal:  Br J Ind Med       Date:  1983-05

Review 7.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 8.  Clinical implications of enzyme induction and enzyme inhibition.

Authors:  B K Park; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

9.  Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease.

Authors:  G C Farrell; W G Cooksley; L W Powell
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

10.  Hepatic microsomal enzyme function in technicians and anesthesiologists exposed to halothane and nitrous oxide.

Authors:  M Døssing; P Weihe
Journal:  Int Arch Occup Environ Health       Date:  1982       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.